Lobbying: all issues, rounded to the nearest $10,000. Two filers, same 21 months. This PAC gives money raised from the company’s employees; the company itself can’t give to campaigns from its treasury.
Spend by quarter Pro
Free account See ProWhat they lobby on
MethodPfizer reported federal lobbying in 8 of the last 8 quarters (Q4 2024 to Q3 2026), with its own in-house lobbyists and 15 outside firms. What follows is what the filings say it lobbied on, not which way.
Issue areas ranked by quarters filedQ4 24 → Q3 26
- Budget/Appropriations8/8
- Copyright/Patent/Trademark8/8
- Defense8/8
- Health Issues8/8
- Medicare/Medicaid8/8
Pharmacy 8 of 8 · Taxation/Internal Revenue Code 8 of 8 · 3 more · Show all 10
- Pharmacy8/8
- Taxation/Internal Revenue Code8/8
- Trade (domestic/foreign)8/8
- Tariff (miscellaneous tariff bills)5/8
- Labor Issues/Antitrust/Workplace4/8
Bills named in the filings 62 bills, this period
- H.R. 1492 To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.11 filings
- H.R. 1 An act to provide for reconciliation pursuant to title II of H. Con. Res. 14. Broad bill11 filings
- S. 1040 Drug Competition Enhancement Act10 filings
- S. 1041 Affordable Prescriptions for Patients Act10 filings
- H.R. 2214 DRUG Act7 filings
57 more, 40 named in only one filing · Show all 62
- S. 2903 / H.R. 5509 Safe Step Act5 filings
- H.R. 1062 Growing and Preserving Innovation in America Act of 20254 filings
- H.R. 1990 American Innovation and R&D Competitiveness Act of 20254 filings
- H.Con.Res. 14 Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Broad bill4 filings
- H.R. 5256 340B ACCESS Act3 filings
- S. 1639 American Innovation and Jobs Act3 filings
- S. 1688 Growing America’s Small Businesses and Manufacturing Act3 filings
- S. 559 / H.R. 1347 AIMM Act3 filings
- H.R. 1458, 118th Access to Prescription Digital Therapeutics Act of 20232 filings
- H.R. 5178 Sickle Cell Disease Comprehensive Care Act2 filings
- H.R. 7837 Most Favored Patient Act of 20262 filings
- H.R. 8816, 118th American Medical Innovation and Investment Act of 20242 filings
- H.R. 9102 BINSA Act2 filings
- H.R. 946 ORPHAN Cures Act2 filings
- S. 2115 / H.R. 4307, 118th Medical Supply Chain Resiliency Act2 filings
- S. 3510 Biosimilar Inspection Modernization Act of 20252 filings
- S. 832 EPIC Act of 20252 filings
- H.R. 1717, 118th Interagency Patent Coordination and Improvement Act of 20231 filing
- H.R. 2213 Medical Supply Chain Resiliency Act1 filing
- H.R. 2450 Prescription Drug Transparency and Affordability Act1 filing
- H.R. 2679, 118th Pharmacy Benefits Manager Accountability Act1 filing
- H.R. 2882 Central Coast of California Conservation Act of 20251 filing
- H.R. 3290, 118th 340B Transparency Act1 filing
- H.R. 4101 Cancer Drug Parity Act of 20251 filing
- H.R. 4299 Protecting Patient Access to Cancer and Complex Therapies Act1 filing
- H.R. 4317 PBM Reform Act of 20251 filing
- H.R. 4581 340B PATIENTS Act of 20251 filing
- H.R. 4822, 118th Health Care Price Transparency Act of 20231 filing
- H.R. 4930 To expand the sharing of information with respect to suspected violations of intellectual property rights in trade.1 filing
- H.R. 5429, 118th Medication Affordability and Patent Integrity Act1 filing
- H.R. 5526 Biosimilar Red Tape Elimination Act1 filing
- H.R. 6986, 118th To address patent thickets.1 filing
- H.R. 7174, 118th To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.1 filing
- H.R. 7391 Community Health Center Drug Pricing Protection Act1 filing
- H.R. 8574, 118th 340B ACCESS Act1 filing
- H.R. 9599 SECURE 340B Act1 filing
- S. 1053 FIGHT China Act of 20251 filing
- S. 113, 118th Prescription Pricing for the People Act of 20231 filing
- S. 142, 118th Preserve Access to Affordable Generics and Biosimilars Act1 filing
- S. 148, 118th Stop STALLING Act1 filing
- S. 150, 118th Affordable Prescriptions for Patients Act of 20231 filing
- S. 187 / H.R. 574 ALIGN Act1 filing
- S. 2333, 118th Pandemic and All-Hazards Preparedness and Response Act1 filing
- S. 2658 Medication Affordability and Patent Integrity Act1 filing
- S. 3131 / H.R. 5539, 118th ORPHAN Cures Act1 filing
- S. 79, 118th Interagency Patent Coordination and Improvement Act of 20231 filing
- H.R. 10545, 118th American Relief Act, 2025 Broad bill1 filing
- H.R. 2673, 118th American Innovation and R&D Competitiveness Act of 2023 Broad bill1 filing
- H.R. 5378, 118th Lower Costs, More Transparency Act Broad bill1 filing
- H.R. 7024, 118th Tax Relief for American Families and Workers Act of 2024 Broad bill1 filing
- H.R. 7148 Consolidated Appropriations Act, 2026 Broad bill1 filing
- H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 Broad bill1 filing
- H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Broad bill1 filing
- S. 127, 118th Pharmacy Benefit Manager Transparency Act of 2023 Broad bill1 filing
- S. 1339, 118th Pharmacy Benefit Manager Reform Act Broad bill1 filing
- S. 2296 National Defense Authorization Act for Fiscal Year 2026 Broad bill1 filing
- S.Con.Res. 7 An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Broad bill1 filing
From the filings
“Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.”
“Issues related to tariff and trade policy.”
Contacted as listed on the filings
- U.S. House
- U.S. Senate
- CMS
- HHS
- USTR
- DOC
- EOP
- FDA
- NEC
- White House Office
- Treasury
- CDC
- 4 more
The House and Senate appear in every quarter; agencies in all 8 quarters.
Every filing since 2015 Pro
Free account See ProSource: Lobbying Disclosure Act filings (LD-2) by Pfizer, Senate Office of Public Records. Filings are due 20 days after each quarter ends.
From FEC filings: direct gifts this PAC reported, net of refunds · How we count
Gave directly to 172 sitting members of Congress and 4 other candidates in 2025–26.
See every candidate and member Pfizer gave to directly, how much, and how its money splits between the parties.
This part is in Pro. A free account lets you follow up to 3 people and get a weekly email about them; upgrade whenever you need more.
Create a free account See what Pro adds Log in